<DOC>
	<DOC>NCT01251276</DOC>
	<brief_summary>Primary objective: =&gt; To describe the Seroprotection rate (SPR) at least 2 years following completion of a primary series with an Hepatitis B vaccine and 1 month following a challenge dose of HBVaxPro. Secondary Objective: =&gt; To describe the safety and tolerability of a challenge dose of HBVaxPro in adults â‰¥50 years of age.</brief_summary>
	<brief_title>Hepatitis B Challenge Dose in Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>In general good health based on a medical history. Received 3 doses of an Hepatitis B vaccine at least 2 years prior to enrollment in this study. Known history of previous Hepatitis B infection. History of vaccination with any Hepatitis B vaccine within the last 2 years. History of febrile illness. Known or suspected hypersensitivity to any component of HBVaxPro. Receipt of medication / vaccine that may interfere with study assessments. Known or suspected immune impairment. Pregnant women and nursing mothers.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>